Your session is about to expire
← Back to Search
Checkpoint Inhibitor
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
Phase 2
Waitlist Available
Led By Adil Daud, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial studies how well a combination of two immune-boosting drugs and aspirin works in treating patients with advanced melanoma that cannot be surgically removed. The treatment aims to help the immune system fight cancer and block cancer cell growth.
Eligible Conditions
- Cutaneous Melanoma
- Melanoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Objective Response Rate (ORR)
Secondary study objectives
Median Duration of PFS
Median Overall Survival (OS)
Number of Participants With Reported Treatment-related Adverse Events
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (pembrolizumab, ipilimumab, aspirin)Experimental Treatment4 Interventions
Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~3150
Aspirin
2014
Completed Phase 4
~55580
Ipilimumab
2015
Completed Phase 3
~3420
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,591 Previous Clinical Trials
14,901,576 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
4,027 Previous Clinical Trials
5,188,776 Total Patients Enrolled
5 Trials studying Cutaneous Melanoma
1,203 Patients Enrolled for Cutaneous Melanoma
Adil Daud, MDPrincipal InvestigatorUniversity of California, San Francisco
6 Previous Clinical Trials
277 Total Patients Enrolled